title: The Portuguese Experience with Ocriplasmin in Clinical Practice.
abstract: OBJECTIVE
  Evaluate the real-life experience with ocriplasmin on vitreomacular traction (VMT) release and full-thickness macular hole (FTMH) closure in Portugal.
  
  
  METHODS
  Multicentric, retrospective study of 83 eyes of 78 patients who were treated with intravitreal ocriplasmin for VMT with and without FTMH. Primary outcomes were VMT release and FTMH closure. Secondary outcomes included visual acuity changes and structural features on spectral-domain ocular coherence tomography.
  
  
  RESULTS
  VMT resolved in 47 of the 83 eyes (56.6%) and 6 of the 12 FTMH were closed (50.0%). Mean best-corrected visual acuity (BCVA) improved from 65.1 at baseline to 70.8 ETDRS letters at the end of follow-up (p < 0.0001) with a mean follow-up of 138.8 days. Improvement in BCVA was significantly better in eyes with VMT release (p = 0.021). Approximately 73% of patients had normal ellipsoid zone integrity at the end of follow-up, 87% had no neurosensorial detachment and 40% had no intra- or subretinal fluid.
  
  
  CONCLUSIONS
  VMT release and FTMH closure were achieved in more than half of the treated eyes and were correlated with significant BCVA improvements and favorable baseline characteristics. In fact, if a careful patient selection is carried out, VMT resolution with ocriplasmin can be optimized, tailoring the best approach to each patient.
authors.affiliation: Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
authors.forename: João
authors.initials: J
authors.lastname: Figueira
authors.forename: David
authors.initials: D
authors.lastname: Martins
authors.forename: Bernardete
authors.initials: B
authors.lastname: Pessoa
authors.forename: Natália
authors.initials: N
authors.lastname: Ferreira
authors.forename: Angelina
authors.initials: A
authors.lastname: Meireles
authors.forename: António
authors.initials: A
authors.lastname: Sampaio
authors.forename: Ângela
authors.initials: Â
authors.lastname: Carneiro
authors.forename: Fernanda
authors.initials: F
authors.lastname: Vaz
authors.forename: João
authors.initials: J
authors.lastname: Nascimento
authors.forename: Natacha
authors.initials: N
authors.lastname: Moreno
authors.forename: José
authors.initials: J
authors.lastname: Roque
authors.forename: Manuel
authors.initials: M
authors.lastname: Domingues
authors.forename: Rita
authors.initials: R
authors.lastname: Flores
authors.forename: Carla
authors.initials: C
authors.lastname: Teixeira
authors.forename: Eduardo
authors.initials: E
authors.lastname: Conde
authors.forename: Filipe
authors.initials: F
authors.lastname: Henriques
authors.forename: Helena
authors.initials: H
authors.lastname: Proença
authors.forename: José
authors.initials: J
authors.lastname: Pita Negrão
authors.forename: Marisa
authors.initials: M
authors.lastname: Barbosa
authors.forename: Rufino
authors.initials: R
authors.lastname: Silva
authors.forename: Sara
authors.initials: S
authors.lastname: Vaz-Pereira
authors.forename: Pedro
authors.initials: P
authors.lastname: Pereira Neves
authors.forename: Nuno
authors.initials: N
authors.lastname: Gomes
authors.forename: Miguel
authors.initials: M
authors.lastname: Raimundo
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome; D014792:Visual Acuity; D020255:Vitreous Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin